Hartaj Singh
Stock Analyst at Oppenheimer
(2.06)
# 2,894
Out of 4,761 analysts
101
Total ratings
41.05%
Success rate
-8.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $0.42 | - | 6 | Dec 11, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $6.81 | +311.16% | 6 | Nov 14, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $95 → $105 | $109.95 | -4.50% | 13 | Nov 7, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,150 → $1,000 | $700.33 | +42.79% | 12 | Nov 6, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $361.10 | +66.16% | 7 | Oct 31, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $550 → $540 | $484.24 | +11.51% | 16 | Oct 30, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $35.53 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $1.53 | +553.59% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $3.46 | +1,634.10% | 5 | May 30, 2024 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $180 | $106.28 | +69.36% | 9 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $2.27 | +296.48% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $2.24 | +1,685.71% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $13.04 | +68.71% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $5.02 | +218.73% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.27 | +51,081.10% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $22.12 | +35.62% | 1 | Jan 26, 2018 |
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.42
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $6.81
Upside: +311.16%
Gilead Sciences
Nov 7, 2024
Maintains: Outperform
Price Target: $95 → $105
Current: $109.95
Upside: -4.50%
Regeneron Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $1,150 → $1,000
Current: $700.33
Upside: +42.79%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $361.10
Upside: +66.16%
Vertex Pharmaceuticals
Oct 30, 2024
Maintains: Outperform
Price Target: $550 → $540
Current: $484.24
Upside: +11.51%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $35.53
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $1.53
Upside: +553.59%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $3.46
Upside: +1,634.10%
Sarepta Therapeutics
May 14, 2024
Upgrades: Outperform
Price Target: $180
Current: $106.28
Upside: +69.36%
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $2.27
Upside: +296.48%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $2.24
Upside: +1,685.71%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $13.04
Upside: +68.71%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $5.02
Upside: +218.73%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.27
Upside: +51,081.10%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $22.12
Upside: +35.62%